587 related articles for article (PubMed ID: 16567633)
1. The mTOR pathway is regulated by polycystin-1, and its inhibition reverses renal cystogenesis in polycystic kidney disease.
Shillingford JM; Murcia NS; Larson CH; Low SH; Hedgepeth R; Brown N; Flask CA; Novick AC; Goldfarb DA; Kramer-Zucker A; Walz G; Piontek KB; Germino GG; Weimbs T
Proc Natl Acad Sci U S A; 2006 Apr; 103(14):5466-71. PubMed ID: 16567633
[TBL] [Abstract][Full Text] [Related]
2. Regulation of mTOR by polycystin-1: is polycystic kidney disease a case of futile repair?
Weimbs T
Cell Cycle; 2006 Nov; 5(21):2425-9. PubMed ID: 17102641
[TBL] [Abstract][Full Text] [Related]
3. Ablation of Long Noncoding RNA Hoxb3os Exacerbates Cystogenesis in Mouse Polycystic Kidney Disease.
Weisser I; Eckberg K; D'Amico S; Buttram D; Aboudehen K
J Am Soc Nephrol; 2024 Jan; 35(1):41-55. PubMed ID: 37953472
[TBL] [Abstract][Full Text] [Related]
4. Double inhibition of cAMP and mTOR signalling may potentiate the reduction of cell growth in ADPKD cells.
de Stephanis L; Bonon A; Varani K; Lanza G; Gafà R; Pinton P; Pema M; Somlo S; Boletta A; Aguiari G
Clin Exp Nephrol; 2017 Apr; 21(2):203-211. PubMed ID: 27278932
[TBL] [Abstract][Full Text] [Related]
5. An mTOR anti-sense oligonucleotide decreases polycystic kidney disease in mice with a targeted mutation in Pkd2.
Ravichandran K; Zafar I; He Z; Doctor RB; Moldovan R; Mullick AE; Edelstein CL
Hum Mol Genet; 2014 Sep; 23(18):4919-31. PubMed ID: 24847003
[TBL] [Abstract][Full Text] [Related]
6. Autophagy activators suppress cystogenesis in an autosomal dominant polycystic kidney disease model.
Zhu P; Sieben CJ; Xu X; Harris PC; Lin X
Hum Mol Genet; 2017 Jan; 26(1):158-172. PubMed ID: 28007903
[TBL] [Abstract][Full Text] [Related]
7. Rapamycin treatment dose-dependently improves the cystic kidney in a new ADPKD mouse model via the mTORC1 and cell-cycle-associated CDK1/cyclin axis.
Li A; Fan S; Xu Y; Meng J; Shen X; Mao J; Zhang L; Zhang X; Moeckel G; Wu D; Wu G; Liang C
J Cell Mol Med; 2017 Aug; 21(8):1619-1635. PubMed ID: 28244683
[TBL] [Abstract][Full Text] [Related]
8. Acute kidney injury induces hallmarks of polycystic kidney disease.
Kurbegovic A; Trudel M
Am J Physiol Renal Physiol; 2016 Oct; 311(4):F740-F751. PubMed ID: 27488998
[TBL] [Abstract][Full Text] [Related]
9. Comparison of folate-conjugated rapamycin versus unconjugated rapamycin in an orthologous mouse model of polycystic kidney disease.
Kipp KR; Kruger SL; Schimmel MF; Parker N; Shillingford JM; Leamon CP; Weimbs T
Am J Physiol Renal Physiol; 2018 Aug; 315(2):F395-F405. PubMed ID: 29717938
[TBL] [Abstract][Full Text] [Related]
10. Inhibition of mTOR with sirolimus slows disease progression in Han:SPRD rats with autosomal dominant polycystic kidney disease (ADPKD).
Wahl PR; Serra AL; Le Hir M; Molle KD; Hall MN; Wüthrich RP
Nephrol Dial Transplant; 2006 Mar; 21(3):598-604. PubMed ID: 16221708
[TBL] [Abstract][Full Text] [Related]
11. Aquaporin-3 deficiency slows cyst enlargement in experimental mouse models of autosomal dominant polycystic kidney disease.
Wang W; Geng X; Lei L; Jia Y; Li Y; Zhou H; Verkman AS; Yang B
FASEB J; 2019 May; 33(5):6185-6196. PubMed ID: 30768374
[TBL] [Abstract][Full Text] [Related]
12. Sirolimus attenuates disease progression in an orthologous mouse model of human autosomal dominant polycystic kidney disease.
Zafar I; Ravichandran K; Belibi FA; Doctor RB; Edelstein CL
Kidney Int; 2010 Oct; 78(8):754-61. PubMed ID: 20686448
[TBL] [Abstract][Full Text] [Related]
13. Polycystic kidney disease and renal injury repair: common pathways, fluid flow, and the function of polycystin-1.
Weimbs T
Am J Physiol Renal Physiol; 2007 Nov; 293(5):F1423-32. PubMed ID: 17715262
[TBL] [Abstract][Full Text] [Related]
14. A mild reduction of food intake slows disease progression in an orthologous mouse model of polycystic kidney disease.
Kipp KR; Rezaei M; Lin L; Dewey EC; Weimbs T
Am J Physiol Renal Physiol; 2016 Apr; 310(8):F726-F731. PubMed ID: 26764208
[TBL] [Abstract][Full Text] [Related]
15. Mammalian target of rapamycin regulates vascular endothelial growth factor-dependent liver cyst growth in polycystin-2-defective mice.
Spirli C; Okolicsanyi S; Fiorotto R; Fabris L; Cadamuro M; Lecchi S; Tian X; Somlo S; Strazzabosco M
Hepatology; 2010 May; 51(5):1778-88. PubMed ID: 20131403
[TBL] [Abstract][Full Text] [Related]
16. Rapamycin ameliorates PKD resulting from conditional inactivation of Pkd1.
Shillingford JM; Piontek KB; Germino GG; Weimbs T
J Am Soc Nephrol; 2010 Mar; 21(3):489-97. PubMed ID: 20075061
[TBL] [Abstract][Full Text] [Related]
17. In vitro cystogenesis: the search for drugs antagonizing cyst development.
Ibraghimov-Beskrovnaya O; Bukanov NO
Nephrol Ther; 2006 Jan; 2 Suppl 2():S109-14. PubMed ID: 17373209
[TBL] [Abstract][Full Text] [Related]
18. Dnajb11-Kidney Disease Develops from Reduced Polycystin-1 Dosage but not Unfolded Protein Response in Mice.
Ghosh Roy S; Li Z; Guo Z; Long KT; Rehrl S; Tian X; Dong K; Besse W
J Am Soc Nephrol; 2023 Sep; 34(9):1521-1534. PubMed ID: 37332102
[TBL] [Abstract][Full Text] [Related]
19. Polycystin-1 but not polycystin-2 deficiency causes upregulation of the mTOR pathway and can be synergistically targeted with rapamycin and metformin.
Mekahli D; Decuypere JP; Sammels E; Welkenhuyzen K; Schoeber J; Audrezet MP; Corvelyn A; Dechênes G; Ong AC; Wilmer MJ; van den Heuvel L; Bultynck G; Parys JB; Missiaen L; Levtchenko E; De Smedt H
Pflugers Arch; 2014 Aug; 466(8):1591-604. PubMed ID: 24193408
[TBL] [Abstract][Full Text] [Related]
20. The inhibition of MDM2 slows cell proliferation and activates apoptosis in ADPKD cell lines.
Patergnani S; Giattino A; Bianchi N; Giorgi C; Pinton P; Aguiari G
Biol Cell; 2023 Jan; 115(1):e2200037. PubMed ID: 36165233
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
